Streptomyces sp.-A Treasure Trove of Weapons to Combat Methicillin-Resistant Staphylococcus aureus Biofilm Associated with Biomedical Devices.
Priyia PusparajahVengadesh LetchumananJodi Woan-Fei LawNurul Syakima Ab MutalibYong Sze OngBey Hing GohLoh Teng Hern TanLearn-Han LeePublished in: International journal of molecular sciences (2021)
Biofilms formed by methicillin-resistant S. aureus (MRSA) are among the most frequent causes of biomedical device-related infection, which are difficult to treat and are often persistent and recurrent. Thus, new and effective antibiofilm agents are urgently needed. In this article, we review the most relevant literature of the recent years reporting on promising anti-MRSA biofilm agents derived from the genus Streptomyces bacteria, and discuss the potential contribution of these newly reported antibiofilm compounds to the current strategies in preventing biofilm formation and eradicating pre-existing biofilms of the clinically important pathogen MRSA. Many efforts are evidenced to address biofilm-related infections, and some novel strategies have been developed and demonstrated encouraging results in preclinical studies. Nevertheless, more in vivo studies with appropriate biofilm models and well-designed multicenter clinical trials are needed to assess the prospects of these strategies.
Keyphrases
- methicillin resistant staphylococcus aureus
- staphylococcus aureus
- biofilm formation
- candida albicans
- pseudomonas aeruginosa
- clinical trial
- systematic review
- emergency department
- case control
- escherichia coli
- cross sectional
- mesenchymal stem cells
- current status
- risk assessment
- quality improvement
- open label
- study protocol
- double blind
- adverse drug
- climate change
- human health